^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Aphexda (motixafortide)
i
Other names: BL-8040, BKT140 SC, TN-14003, BKT 140, BL 8040, TF-14016, 4F-benzoyl-TN14003, BKT-140
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Ayrmid, BioLineRx, GenFleet Therap, Gloria Pharma
Drug class:
CXCR4 antagonist
Related drugs:
2ms
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients (clinicaltrials.gov)
P3, N=60, Recruiting, Guangzhou Gloria Biosciences Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Aug 2026 --> Dec 2026
Enrollment open • Trial completion date • Trial primary completion date
|
Aphexda (motixafortide)
2ms
MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov)
P1/2, N=214, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | N=410 --> 214
Trial completion • Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
HER-2 negative • HER-2 expression
|
cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)
2ms
A human iPSC-based neural spheroid platform for modelling glioblastoma infiltration using high-content imaging. (PubMed, Sci Rep)
A proof-of-principle drug screen identified PF 573228 (FAK inhibitor) and motixafortide (CXCR4 inhibitor) as potent suppressors of GBM20 and GBM1 infiltration, respectively. Bulk RNA sequencing revealed gene expression profiles correlating with invasive behaviour and drug sensitivity. This platform offers a valuable model for studying glioblastoma infiltration along axons and provides proof-of-principle that migration can serve as a measurable and actionable phenotype to screen therapeutic vulnerabilities in glioblastoma.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
Aphexda (motixafortide) • PF-573228
2ms
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (clinicaltrials.gov)
P4, N=94, Recruiting, Emory University | Not yet recruiting --> Recruiting
Enrollment open
|
Hemady (dexamethasone tablets) • Aphexda (motixafortide)
5ms
SCD Stem Cell Mobilization and Apheresis Using Motixafortide (clinicaltrials.gov)
P1, N=15, Recruiting, St. Jude Children's Research Hospital | Trial completion date: Jul 2026 --> Jul 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
Trial completion date • Trial primary completion date
|
Aphexda (motixafortide)
5ms
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization (clinicaltrials.gov)
P1, N=20, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
Trial completion
|
Aphexda (motixafortide)
6ms
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (clinicaltrials.gov)
P4, N=94, Not yet recruiting, Emory University
New P4 trial
|
Hemady (dexamethasone tablets) • Aphexda (motixafortide)
6ms
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization (clinicaltrials.gov)
P1, N=20, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Aug 2025 | Trial primary completion date: Jan 2026 --> Jul 2025
Enrollment closed • Trial completion date • Trial primary completion date
|
Aphexda (motixafortide)
7ms
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) (clinicaltrials.gov)
P1, N=10, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
Trial completion
|
Aphexda (motixafortide) • Tysabri (natalizumab)
9ms
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) (clinicaltrials.gov)
P1, N=10, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2025 --> Jun 2025 | Trial primary completion date: Dec 2025 --> Jun 2025
Trial completion date • Trial primary completion date
|
Aphexda (motixafortide) • Tysabri (natalizumab)
9ms
MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov)
P1/2, N=410, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2025 --> Sep 2025
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
HER-2 negative • HER-2 expression
|
cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)
10ms
MORPHEUS-PDAC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (clinicaltrials.gov)
P1/2, N=341, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • gemcitabine • 5-fluorouracil • Cotellic (cobimetinib) • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Actemra IV (tocilizumab) • tiragolumab (RG6058) • etrumadenant (AB928) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide) • selicrelumab (RG7876) • simlukafusp alfa (RG7461)
Share via
